{"filing":{"accession_number":"0001104659-26-076624","cik":"0001875558","ticker":"NVCT","company_name":"Nuvectis Pharma, Inc.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"tm2618439d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926076624/tm2618439d1_8k.htm"},"events":[{"id":12971,"run_id":11513,"accession_number":"0001104659-26-076624","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.94,"summary":"Nuvectis entered into a material definitive license agreement with Haisco Pharmaceutical Group on June 22, 2026, acquiring exclusive ex-China rights to develop, manufacture, and commercialize two clinical-stage drug candidates (NXP100 and NXP200). The transaction involves an upfront payment of $20 million, up to $20 million in initial development milestones, and up to $1.4 billion in contingent payments, representing a material acquisition of intellectual property and development rights that transforms the company's pipeline and strategy.","company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":9979,"accession_number":"0001104659-26-076624","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Nuvectis entered into a material definitive license agreement with Haisco on June 22, 2026, acquiring exclusive ex-China rights to develop, manufacture, and commercialize two clinical-stage drug candidates (NXP100 and NXP200). The transaction involves an upfront payment of $20 million, up to $20 million in initial development milestones, and up to $1.4 billion in contingent payments, representing a material acquisition of intellectual property and development rights that transforms the company's pipeline and strategy. This constitutes a material acquisition activity under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T11:01:52.477643+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9980,"accession_number":"0001104659-26-076624","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Nuvectis entered into a license agreement with Haisco Pharmaceutical Group to acquire exclusive ex-China rights to two clinical-stage drug candidates (NXP100 and NXP200). The transaction involves upfront payments of up to $40 million plus up to $1.421 billion in milestone payments and royalties, representing a material expansion of the company's pipeline and strategic direction. This constitutes a material acquisition of intellectual property and development rights that would significantly affect investor assessment of the registrant's future prospects and capital allocation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T11:01:52.477643+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9979,"accession_number":"0001104659-26-076624","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Nuvectis entered into a material definitive license agreement with Haisco on June 22, 2026, acquiring exclusive ex-China rights to develop, manufacture, and commercialize two clinical-stage drug candidates (NXP100 and NXP200). The transaction involves an upfront payment of $20 million, up to $20 million in initial development milestones, and up to $1.4 billion in contingent payments, representing a material acquisition of intellectual property and development rights that transforms the company's pipeline and strategy. This constitutes a material acquisition activity under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T11:01:52.477643+00:00","company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","filing_date":"2026-06-23"},{"id":9980,"accession_number":"0001104659-26-076624","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Nuvectis entered into a license agreement with Haisco Pharmaceutical Group to acquire exclusive ex-China rights to two clinical-stage drug candidates (NXP100 and NXP200). The transaction involves upfront payments of up to $40 million plus up to $1.421 billion in milestone payments and royalties, representing a material expansion of the company's pipeline and strategic direction. This constitutes a material acquisition of intellectual property and development rights that would significantly affect investor assessment of the registrant's future prospects and capital allocation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T11:01:52.477643+00:00","company_name":"Nuvectis Pharma, Inc.","ticker":"NVCT","filing_date":"2026-06-23"}]}